Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD

Summary

Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD

Timeline

Start

2024-04-16

Primary completion

2026-01-28

Completion

2026-02-24

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

release “announced positive results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.” corvuspharma.com ↗

Drugs

Indications